{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-024918","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.412491+00:00","generated_at":"2026-05-15T17:39:51.718749+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relmada raises $160M private placement; NDV-01 12-month Phase 2 CR rate 76%","bullets":["Oversubscribed PIPE financing of ~$160M gross from 29.47M shares at $4.75/share plus pre-funded warrants, expected to close March 11, 2026.","Proceeds to be used for working capital and advancing R&D of product candidates, including NDV-01.","NDV-01 Phase 2 in high-risk NMIBC: 12-month complete response rate 76% overall, 80% in BCG-unresponsive patients.","No Grade 3+ treatment-related adverse events; no patient progressed to muscle-invasive disease or required cystectomy.","Phase 3 RESCUE program planned for mid-2026 with two registrational pathways: 2L BCG-unresponsive and adjuvant intermediate-risk NMIBC."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-024918","json":"https://secwatch.observer/filing/0001213900-26-024918.json","markdown":"https://secwatch.observer/filing/0001213900-26-024918.md","text":"https://secwatch.observer/filing/0001213900-26-024918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/0001213900-26-024918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/ea0280436-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:39:51.718749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ea53c9c6586ef4157c436b93f3ad403bd8f5ba9","claim":"RELMADA THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $160.0 million (effective 2026-03-09).","evidence_excerpt":"On March 9, 2026, Relmada Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/0001213900-26-024918-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $160.0 million"},{"label":"Effective","value":"2026-03-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}